Fees for services under the Gene Technology Act to change
Fees for services under the Gene Technology Act to change
A Government Decree (1195/2025) has been issued setting the fees for notifications, applications, and supervision under the Gene Technology Act (377/1995) for the years 2026–2027. The Decree enters into force on 1 January 2026 and is valid until 30 April 2027.
Fees for processing notifications and applications for contained use and deliberate release will increase by approximately 25%. Some new fees will also be introduced:
- A separate fee will now be charged in cases where a new clinical trial related to a previously submitted notification for contained use is started in accordance with section 16 d of the Gene Technology Act using only a risk assessment procedure.
- The processing of later changes and reports related to approved field trials will become subject to a fee if they require a decision from the Board for Gene Technology.
- The hourly fee for inspections carried out by the supervisory authorities will remain unchanged but may be charged for a greater maximum number of hours than before. The fee for Fimea’s written inspection will also increase.
The new fees under the Decree will apply to chargeable services initiated after 1 January 2026.
